{"id":1959,"date":"2025-03-20T08:00:00","date_gmt":"2025-03-20T12:00:00","guid":{"rendered":"https:\/\/9bio.ca\/?p=1959"},"modified":"2026-01-20T09:25:24","modified_gmt":"2026-01-20T14:25:24","slug":"9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation","status":"publish","type":"post","link":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/","title":{"rendered":"9Bio Th\u00e9rapeutiques et TransBIOTech obtiennent une subvention de recherche et d\u00e9veloppement appliqu\u00e9e (RDA) de 450 000 $ pour acc\u00e9l\u00e9rer l\u2019innovation en oncologie"},"content":{"rendered":"<p class=\"has-text-align-center\"><em><strong>Ce financement pluriannuel a pour objectif de faire progresser des th\u00e9rapies prometteuses contre le cancer en effectuant des \u00e9tudes pr\u00e9cliniques de toxicit\u00e9 et d\u2019efficacit\u00e9 n\u00e9cessaires \u00e0 l\u2019obtention des approbations r\u00e9glementaires pour les essais cliniques<\/strong><\/em><\/p>\n\n\n\n<p><strong>Qu\u00e9bec, QC, le 20 mars 2025<\/strong> \u2013 9Bio Th\u00e9rapeutiques, une entreprise de biotechnologie sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies oncologiques de nouvelle g\u00e9n\u00e9ration, annonce aujourd\u2019hui, en partenariat avec TransBIOTech (L\u00e9vis, QC), l\u2019obtention d\u2019une subvention de 450 000 $. Ce financement en recherche et d\u00e9veloppement appliqu\u00e9e (RDA) est attribu\u00e9 dans le cadre du programme d\u2019innovation dans les coll\u00e8ges et la communaut\u00e9 (ICC), administr\u00e9 par le Conseil de recherches en sciences naturelles et en g\u00e9nie du Canada (CRSNG), en collaboration avec le Conseil de recherches en sciences humaines (CRSH) et les Instituts de recherche en sant\u00e9 du Canada (IRSC).<\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-ed7f7844cd01f2137a3ca4351827b28e\">Cet investissement f\u00e9d\u00e9ral, r\u00e9parti sur trois ans, permet \u00e0 9Bio Th\u00e9rapeutiques de tirer parti de l\u2019expertise reconnue de TransBIOTech en recherche pr\u00e9clinique afin de faire progresser son portfolio innovant de th\u00e9rapies cibl\u00e9es en oncologie. En compl\u00e9ment <a href=\"https:\/\/9bio.ca\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/\">d\u2019une subvention Partenar-IA r\u00e9cemment accord\u00e9e par le CQDM<\/a>, ce financement permettra d\u2019acc\u00e9l\u00e9rer le d\u00e9veloppement de deux candidats th\u00e9rapeutiques vers les essais cliniques, renfor\u00e7ant ainsi la position du Canada en tant que leader mondial en biotechnologie.<\/p>\n\n\n\n<p>TransBIOTech, Centre coll\u00e9gial de transfert de technologie (CCTT) et organisme \u00e0 but non lucratif sp\u00e9cialis\u00e9 en recherche appliqu\u00e9e dont le d\u00e9veloppement pr\u00e9clinique de m\u00e9dicaments candidats, apportera son expertise \u00e9tablie en \u00e9tudes pr\u00e9cliniques n\u00e9cessaires pour satisfaire les autorit\u00e9s r\u00e9glementaires. Ces \u00e9tudes incluent notamment des tests fonctionnels sur le syst\u00e8me immunitaire, l\u2019\u00e9valuation de la destruction des cellules tumorales, ainsi que des \u00e9tudes in vivo sur la pharmacocin\u00e9tique, l\u2019efficacit\u00e9 et le m\u00e9canisme d\u2019action des th\u00e9rapies candidates. Ces essais soutiendront les soumissions r\u00e9glementaires et faciliteront la progression vers les essais cliniques.<\/p>\n\n\n\n<p>Les mol\u00e9cules th\u00e9rapeutiques \u00e9valu\u00e9es dans ces \u00e9tudes proviennent des efforts de d\u00e9couverte de 9Bio et seront fournies par 9Bio, qui conservera l\u2019enti\u00e8re ma\u00eetrise de leur d\u00e9veloppement, de leur strat\u00e9gie r\u00e9glementaire et de leur commercialisation. Conform\u00e9ment \u00e0 son mod\u00e8le d\u2019affaires, TransBIOTech ne revendiquera aucun droit de propri\u00e9t\u00e9 intellectuelle (PI) dans le cadre de cet accord.<\/p>\n\n\n\n<p>\u00ab La plateforme de 9Bio exploite la puissance de la biologie computationnelle pour d\u00e9velopper rapidement des th\u00e9rapies conditionnellement actives. La validation de nos mod\u00e8les et le d\u00e9veloppement de nos th\u00e9rapies n\u00e9cessitent des technologies de pointe et une expertise scientifique d\u2019excellence, \u00bb a d\u00e9clar\u00e9 Philipe Gobeil, cofondateur, pr\u00e9sident et directeur scientifique de 9Bio Th\u00e9rapeutiques. \u00ab Cette collaboration avec TransBIOTech s\u2019inscrit comme un \u00e9l\u00e9ment cl\u00e9 de notre strat\u00e9gie de d\u00e9veloppement pr\u00e9clinique et acc\u00e9l\u00e9rera notre transition vers les essais cliniques. \u00bb<\/p>\n\n\n\n<p>Fred Couture, Ph. D., chercheur principal et responsable des sciences pharmaceutiques chez TransBIOTech, ajoute : \u00ab Nous sommes ravis de soutenir les travaux de 9Bio et de contribuer \u00e0 l\u2019avancement de th\u00e9rapies novatrices. Ce financement souligne l\u2019importance des collaborations en recherche appliqu\u00e9e pour faire progresser l\u2019innovation en biotechnologie et offrir de nouveaux traitements aux patients qui ne r\u00e9pondent pas aux th\u00e9rapies actuelles ou qui n\u00e9cessitent des options plus tol\u00e9rables. Avec les co-chercheurs Prof. Yvan Boutin et Prof. Marie-Eve Janelle, nous mettrons notre expertise au service de l\u2019acc\u00e9l\u00e9ration du d\u00e9veloppement pr\u00e9clinique de 9Bio. \u00bb<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>\u00c0 propos de 9Bio Th\u00e9rapeutiques<\/strong><\/p>\n\n\n\n<p>9Bio est une entreprise de biotechnologie d\u00e9di\u00e9e au d\u00e9veloppement de th\u00e9rapies oncologiques innovantes. Notre plateforme de biologie structurale guid\u00e9e par l'IA int\u00e8gre des contextes anatomiques et biochimiques pour concevoir des m\u00e9dicaments ciblant s\u00e9lectivement les tumeurs. Gr\u00e2ce \u00e0 cette approche, nous d\u00e9veloppons des traitements sp\u00e9cifiquement dirig\u00e9s contre les tumeurs, tout en pr\u00e9servant les tissus sains, am\u00e9liorant ainsi la s\u00e9curit\u00e9, l\u2019efficacit\u00e9 et ouvrant la voie \u00e0 des modalit\u00e9s th\u00e9rapeutiques jusqu\u2019ici sous-exploit\u00e9es. Notre pipeline comprend deux th\u00e9rapies en phase de d\u00e9couverte : un conjugu\u00e9 anticorps-m\u00e9dicament (ADC) ciblant les cellules tumorales chimior\u00e9sistantes et un autre ADC ciblant les cellules immunitaires subverties par les tumeurs.<\/p>\n\n\n\n<p><strong>\u00c0 propos TransBIOTech<\/strong><\/p>\n\n\n\n<p class=\"has-theme-palette-9-color has-text-color has-link-color wp-elements-1d87bf71efd38cd37ffc4c3f17ec4328\">TransBIOTech, un Centre coll\u00e9gial de transfert de technologie (CCTT) affili\u00e9 au C\u00e9gep de L\u00e9vis, QC, Canada, est un organisme \u00e0 but non lucratif sp\u00e9cialis\u00e9 en biotechnologie. Depuis 1999, TransBIOTech offre un soutien expert en d\u00e9veloppement de m\u00e9dicaments, proposant des services en pharmacologie, biologie cellulaire et mol\u00e9culaire, biochimie, pharmacocin\u00e9tique et toxicologie. Les chercheurs de TransBIOTech utilisent leur expertise et des m\u00e9thodologies avanc\u00e9es pour \u00e9valuer le m\u00e9canisme d\u2019action, l\u2019efficacit\u00e9 et l\u2019innocuit\u00e9 des candidats th\u00e9rapeutiques \u00e0 diff\u00e9rentes \u00e9tapes du d\u00e9veloppement pr\u00e9clinique. Pour plus d\u2019information <a href=\"https:\/\/www.transbio.tech\" target=\"_blank\" rel=\"noreferrer noopener\">www.transbio.tech<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>En partenariat avec TransBIOTech (L\u00e9vis, QC), 9Bio Th\u00e9rapeutiques annonce aujourd\u2019hui l\u2019obtention d\u2019une subvention de 450 000 $. Ce financement en recherche et d\u00e9veloppement appliqu\u00e9e (RDA) est attribu\u00e9 dans le cadre du programme d\u2019innovation dans les coll\u00e8ges et la communaut\u00e9 (ICC), administr\u00e9 par le Conseil de recherches en sciences naturelles et en g\u00e9nie du Canada (CRSNG), en collaboration avec le Conseil de recherches en sciences humaines (CRSH) et les Instituts de recherche en sant\u00e9 du Canada (IRSC).<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-1959","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation - 9Bio Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation - 9Bio Therapeutics\" \/>\n<meta property=\"og:description\" content=\"In partnership with TransBIOTech (Levis, QC), 9Bio Therapeutics has been awarded a $450,000 Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program, administered through the Natural Sciences and Engineering Research Council of Canada (NSERC) in collaboration with the Social Sciences and Humanities Research Council (SSHRC) and Canadian Institutes of Health Research (CIHR).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"9Bio Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T12:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T14:25:24+00:00\" \/>\n<meta name=\"author\" content=\"Henrique de Carvalho\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Henrique de Carvalho\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\\\/\"},\"author\":{\"name\":\"Henrique de Carvalho\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\"},\"headline\":\"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation\",\"datePublished\":\"2025-03-20T12:00:00+00:00\",\"dateModified\":\"2026-01-20T14:25:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\\\/\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\\\/\",\"name\":\"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation - 9Bio Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\"},\"datePublished\":\"2025-03-20T12:00:00+00:00\",\"dateModified\":\"2026-01-20T14:25:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/news\\\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/9biotx.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#website\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"name\":\"9Bio Therapeutics\",\"description\":\"Engineering Biological Possibilities\",\"publisher\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/9biotx.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#organization\",\"name\":\"9Bio Therapeutics\",\"url\":\"https:\\\/\\\/9biotx.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"contentUrl\":\"https:\\\/\\\/9biotx.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/9Bio-therapeutics-transparent-background-tangerine-small.png\",\"width\":200,\"height\":80,\"caption\":\"9Bio Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/9bio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/9biotx.com\\\/#\\\/schema\\\/person\\\/eda3764256a793b2350112b46b0169a8\",\"name\":\"Henrique de Carvalho\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g\",\"caption\":\"Henrique de Carvalho\"},\"sameAs\":[\"https:\\\/\\\/9bio.ca\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation - 9Bio Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/","og_locale":"fr_CA","og_type":"article","og_title":"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation - 9Bio Therapeutics","og_description":"In partnership with TransBIOTech (Levis, QC), 9Bio Therapeutics has been awarded a $450,000 Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program, administered through the Natural Sciences and Engineering Research Council of Canada (NSERC) in collaboration with the Social Sciences and Humanities Research Council (SSHRC) and Canadian Institutes of Health Research (CIHR).","og_url":"https:\/\/9biotx.com\/fr\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/","og_site_name":"9Bio Therapeutics","article_published_time":"2025-03-20T12:00:00+00:00","article_modified_time":"2026-01-20T14:25:24+00:00","author":"Henrique de Carvalho","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Henrique de Carvalho","Estimation du temps de lecture":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/#article","isPartOf":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/"},"author":{"name":"Henrique de Carvalho","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8"},"headline":"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation","datePublished":"2025-03-20T12:00:00+00:00","dateModified":"2026-01-20T14:25:24+00:00","mainEntityOfPage":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/"},"wordCount":586,"publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"articleSection":["News"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/","url":"https:\/\/9biotx.com\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/","name":"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation - 9Bio Therapeutics","isPartOf":{"@id":"https:\/\/9biotx.com\/#website"},"datePublished":"2025-03-20T12:00:00+00:00","dateModified":"2026-01-20T14:25:24+00:00","breadcrumb":{"@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/9biotx.com\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/9biotx.com\/news\/9bio-therapeutics-and-transbiotech-awarded-450000-applied-research-and-development-ard-grant-to-accelerate-oncology-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/9biotx.com\/"},{"@type":"ListItem","position":2,"name":"9Bio Therapeutics and TransBIOTech awarded $450,000 Applied Research and Development (ARD) grant to accelerate oncology innovation"}]},{"@type":"WebSite","@id":"https:\/\/9biotx.com\/#website","url":"https:\/\/9biotx.com\/","name":"9Bio Th\u00e9rapeutiques","description":"Engineering Biological Possibilities","publisher":{"@id":"https:\/\/9biotx.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/9biotx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/9biotx.com\/#organization","name":"9Bio Th\u00e9rapeutiques","url":"https:\/\/9biotx.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/","url":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","contentUrl":"https:\/\/9biotx.com\/wp-content\/uploads\/2024\/10\/9Bio-therapeutics-transparent-background-tangerine-small.png","width":200,"height":80,"caption":"9Bio Therapeutics"},"image":{"@id":"https:\/\/9biotx.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/9bio\/"]},{"@type":"Person","@id":"https:\/\/9biotx.com\/#\/schema\/person\/eda3764256a793b2350112b46b0169a8","name":"Henrique de Carvalho","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0627e8f747d51e00b97aadc1c41d88c0c04f1f314d881b75f519fbbc5468f8a?s=96&d=mm&r=g","caption":"Henrique de Carvalho"},"sameAs":["https:\/\/9bio.ca"]}]}},"taxonomy_info":{"category":[{"value":1,"label":"News"}]},"featured_image_src_large":false,"author_info":{"display_name":"Henrique de Carvalho","author_link":"https:\/\/9biotx.com\/fr\/news\/author\/decarvalho\/"},"comment_info":0,"category_info":[{"term_id":1,"name":"News","slug":"news","term_group":0,"term_taxonomy_id":1,"taxonomy":"category","description":"9Bio News","parent":0,"count":7,"filter":"raw","cat_ID":1,"category_count":7,"category_description":"9Bio News","cat_name":"News","category_nicename":"news","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/comments?post=1959"}],"version-history":[{"count":6,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1959\/revisions"}],"predecessor-version":[{"id":1990,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/posts\/1959\/revisions\/1990"}],"wp:attachment":[{"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/media?parent=1959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/categories?post=1959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/9biotx.com\/fr\/wp-json\/wp\/v2\/tags?post=1959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}